Design and rationale of the EBBINGHAUS trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid‐lowering therapy—A cognitive study of patients enrolled in the FOURIER trial

Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. Similar questions were raised regarding proprotein convertase subtilisin/kexin‐type 9 inhibitors (PCSK9i) and neurocognitive function. No prospectively designed s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cardiol
Main Authors: Giugliano, Robert P., Mach, Francois, Zavitz, Kenton, Kurtz, Christopher, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R., Sabatine, Marc S., Sever, Peter S., Honarpour, Narimon, Wasserman, Scott M., Ott, Brian R.
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Periodicals, Inc. 2017
Assuntos:
Trial Designs
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490624/
https://ncbi.nlm.nih.gov/pubmed/28207168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22678
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados